Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

Introduction: Targeted agents such as bevacizumab (BEV) or poly (ADP-ribose) polymerase inhibitors (PARPi) which have been added as concomitant or maintenance therapies have been shown to improve progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer (PS rOC). I...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Mol Sci
Main Authors: Bartoletti, Michele, Pelizzari, Giacomo, Gerratana, Lorenzo, Bortot, Lucia, Lombardi, Davide, Nicoloso, Milena, Scalone, Simona, Giorda, Giorgio, Baldassarre, Gustavo, Sorio, Roberto, Puglisi, Fabio
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7312982/
https://ncbi.nlm.nih.gov/pubmed/32471250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21113805
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares